title: Risedronate for the prevention of hip fractures: concern about validity of trials.
authors.forename: Jutta Martha
authors.initials: JM
authors.lastname: Halbekath
authors.forename: Stefanie
authors.initials: S
authors.lastname: Schenk
authors.forename: Andreas
authors.initials: A
authors.lastname: von Maxen
authors.forename: Gabriele
authors.initials: G
authors.lastname: Meyer
authors.forename: Ingrid
authors.initials: I
authors.lastname: Mühlhauser
mesh_terms: D000368:Aged; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006620:Hip Fractures / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic / Q000592:standards*; D015203:Reproducibility of Results; D012189:Retrospective Studies; D000068296:Risedronic Acid; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid